Hiroji Iwata, MD, PhD, Aichi Cancer Center Hospital, Nagoya, Japan, presents the primary analysis from the NEOS trial, a randomized Phase III study that assessed the long-term prognosis of patients with estrogen receptor-positive (ER+) primary breast cancer who received neoadjuvant endocrine therapy with or without adjuvant chemotherapy. This interview took place at the San Antonio Breast Cancer Symposium 2021 in San Antonio.